Page last updated: 2024-11-04

isradipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isradipine is a calcium channel blocker used primarily for the treatment of hypertension. It works by inhibiting the influx of calcium ions into smooth muscle cells, causing relaxation of blood vessels and a reduction in blood pressure. Isradipine is synthesized through a multi-step process that involves several organic reactions. Due to its effectiveness in lowering blood pressure and its relatively long duration of action, isradipine is widely studied to understand its potential for treating cardiovascular disease and other conditions. Research focuses on investigating its mechanisms of action, efficacy, safety, and potential interactions with other medications.'

coelenteramide: part of blue fluorescent protein; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID448487
CHEBI ID41487
SCHEMBL ID134644
MeSH IDM0026221
PubMed CID3784
CHEMBL ID315436
CHEMBL ID1648
CHEMBL ID3211306
CHEBI ID6073
SCHEMBL ID34555
MeSH IDM0026221

Synonyms (186)

Synonym
CEI ,
n-[3-benzyl-5-(4-hydroxyphenyl)pyrazin-2-yl]-2-(4-hydroxyphenyl)acetamide
50611-86-4
CHEBI:41487
DB04049
coelenteramide
2PSJ
oplophorus oxyluciferin
SCHEMBL134644
CJIIERPDFZUYPI-UHFFFAOYSA-N
3-benzyl-5-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)acetylamino]pyrazine
DTXSID10416113
JIAUJOOGSKJAFH-UHFFFAOYSA-N
Q5140606
s5msb8rf66 ,
2-(p-hydroxyphenylacetyl)amino-3-benzyl-5-(p-hydroxyphenyl)pyrazine
2-(4-hydroxyphenyl)-n-(5-(4-hydroxyphenyl)-3-(phenylmethyl)pyrazin-2-yl)ethanamide
oxyluciferin (oplophorus)
CS-0372386
HY-145385
4-hydroxy-n-[5-(4-hydroxyphenyl)-3-(phenylmethyl)-2-pyrazinyl]benzeneacetamide
3-benzyl-5-(4-hydroxyphenyl)-2-[[(4-hydroxyphenyl)acetyl]amino]pyrazi
benzeneacetamide, 4-hydroxy-n-[5-(4-hydroxyphenyl)-3-(phenylmethyl)-2-pyrazinyl]-
CHEMBL315436
MLS002154106
o5-methyl o3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
HMS3393J12
HMS3268D21
BRD-A90799790-001-03-3
pn-200110
icaz
dynacirc cr
methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
isradipine, >=98% (hplc), solid
SPECTRUM_000218
PRESTWICK2_001021
NCGC00025341-01
BSPBIO_001201
BPBIO1_001323
4-(4-benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
4-(2,1,3-benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic acid methyl ester
3,5-pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester
clivoten
75695-93-1
dynacirc
isrodipine
dynacrine
isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate
lomir
4-(4-benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester
(+/-)-isradipine
dynacire cr
pn 200
3,5-pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester
isradipine
pn 200-110
rebriden
isradipin
3,5-pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9ci)
esradin
dynacire
prescal
MLS001424076
AB00514007
smr000466320
MLS000759425
DB00270
D00349
dynacirc (tn)
isradipine (usp/inn)
PRESTWICK3_001021
(+-)-isradipine
isradipinum [latin]
isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
isradipino [spanish]
3,5-pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (+-)-
pn-200-110
c19h21n3o5
KBIO2_000698
KBIO2_003266
KBIO2_005834
KBIOSS_000698
PRESTWICK0_001021
SPBIO_003062
PRESTWICK1_001021
NCGC00025341-03
NCGC00025341-02
HMS2051J12
HMS1571M03
nsc-759892
CHEMBL1648
3-o-methyl 5-o-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
HMS2098M03
yo1uk1s598 ,
nsc 759892
isradipino
isradipinum
unii-yo1uk1s598
isradipine [usan:usp:inn:ban]
nsc759892
pharmakon1600-02300234
dtxcid203179
dtxsid4023179 ,
tox21_110690
HMS2235O12
CCG-101027
MLS003915633
smr002529690
FT-0627542
bdbm50436176
S1662
AKOS015895129
4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
(plusmn)-isradipine
gtpl4488
isradipine [usp-rs]
isopropyl methyl (+/-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
isradipine [orange book]
isradipine [usan]
isradipine [mart.]
isradipine [inn]
isradipine [vandf]
isradipine [who-dd]
3,5-pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (+/-)-
isradipine [ep monograph]
isradipine [usp monograph]
isradipine [mi]
CCG-213711
HY-B0233
MLS006010138
NC00277
SCHEMBL34555
NCGC00025341-06
tox21_110690_1
HS-0085
isopropyl methyl (.+/-.)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
3,5-pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (.+/-.)-
isopropyl methyl (.+/-.)-4-(4-benzfurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
3-isopropyl 5-methyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate #
(.+/-.)-isradipine
4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester
isradipine (dynacirc)
HB1223
3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CHEMBL3211306
isopropyl methyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimet
isopropyl methyl 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid isopropyl methyl ester
I0876
AB00514007_03
AB00514007_02
mfcd00153820
benzo[1,2,5]oxadiazol-4-aldehyde
3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
J-513454
SR-01000597526-1
AC-8539
sr-01000597526
SR-01000597526-2
isradipine, united states pharmacopeia (usp) reference standard
HMS3655C17
isradipine, european pharmacopoeia (ep) reference standard
isradipine; methyl 1-methylethyl (4rs)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CHEBI:6073
HMS3715M03
SW220017-1
131970-21-3
BCP06719
Q414873
HMS3677A15
HMS3413A15
BRD-A90799790-001-10-8
HMS3884E06
SR-01000597526-8
EN300-19741623
PD002963
PD033063
isradipinum (latin)
isradipine (usp monograph)
isradipina
isradipine (usp-rs)
isradipine (usan:usp:inn:ban)
c08ca03
isradipine (mart.)
isradipine (ep monograph)
isopropyl methyl(+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate

Research Excerpts

Overview

Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration-dependent neuroprotective effects in animal models of Parkinson's disease (PD) But failed to show efficacy in a phase 3 clinical trial.

ExcerptReferenceRelevance
"Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration-dependent neuroprotective effects in animal models of Parkinson's disease (PD) but failed to show efficacy in a phase 3 clinical trial. "( Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
James Surmeier, D; Javidnia, M; Oakes, D; Simuni, T; Venuto, CS; Yang, L, 2021
)
3.51
"Isradipine (ISR) is a potent calcium channel blocker with low oral bioavailability due to low aqueous solubility, extensive first-pass metabolism and P-glycoprotein (P-gp)-mediated efflux transport. "( Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
Bandari, S; Eedara, BB; Jukanti, R; Kandadi, P; Ramasahayam, B, 2015
)
2.21
"Isradipine (ID), is an antihypertensive drug, having low oral bioavailability (15-24%) due to poor aqueous solubility (0.01 mg/mL) and also hepatic first-pass metabolism. "( Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Narendar, D; Swetha, E; Thirupathi, G, 2017
)
2.33
"Isradipine (ISDP) is an effective calcium channel blocker used in the treatment of hypertension. "( Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics.
Gannu, R; Jangala, VR; Khagga, M; Tirunagari, M, 2010
)
2.08
"Isradipine is a Federal Drug Administration-approved dihydropyridine calcium channel blocker that binds selectively to Ca(v)1.2 in the hippocampus."( Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.
Anekonda, TS; Quinn, JF, 2011
)
1.31
"Isradipine is a known inhibitor of the CYP450 isoenzyme family. "( Phenytoin/isradipine interaction causing severe neurologic toxicity.
Cachat, F; Tufro, A, 2002
)
2.16
"Isradipine (PN 200-110) is a highly potent calcium entry blocker with an asymmetrically substituted dihydropyridine ring (methyl- and isopropylester, respectively). "( Stereoselective binding of isradipine to human plasma proteins.
Bencsíková, E; Bohov, P; Oravcová, J; Sojková, D; Trnovec, T, 1995
)
2.03
"Isradipine is an approved antihypertensive agent, but its antianginal effects have not been well documented."( Duration of effects of isradipine during twice daily therapy in angina pectoris.
Archer, S; Chrysant, S; Copen, D; Giles, T; Gorwit, J; Hobbs, S; Iteld, B; Singh, S; Thadani, U; Wakeford, C, 1994
)
1.32
"Isradipine is a dihydropyridine calcium-entry blocker. "( A large, prospective, open-label study of isradipine in patients with essential hypertension. The Isradipine Investigators Group.
Weiss, RJ,
)
1.84
"Isradipine is a dihydropyridine calcium antagonist used for the treatment of hypertension. "( Cardiac effects of isradipine in patients with hypertension.
Lund-Johansen, P, 1993
)
2.06
"Isradipine SRO is an effective and well-tolerated antihypertensive agent and combination with spirapril appears to enhance its efficacy without an increase in side-effects."( Efficacy of slow-release oral isradipine in moderate-to-severe hypertension with add-on spirapril.
Abarquez, RF; Castillo, RR; Sy, RG, 1993
)
1.3
"Isradipine may prove to be a safe antihypertensive treatment in patients with impaired ventricular function (cardiac failure), impaired myocardial perfusion (ischaemia), and in cases of selected conduction abnormalities or arrhythmias."( Haemodynamics and tissue specificity with isradipine.
Leslie, JB, 1993
)
1.27
"Isradipine is a new dihydropyridine-derived calcium antagonist. "( Isradipine: a profile in essential hypertension.
Hansson, L, 1993
)
3.17
"Isradipine is a new dihydropyridine calcium antagonist reported to have minimal effects on cardiac electrophysiology. "( A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil.
Coutinho, N; Goldman, I; Landau, S; Somberg, J; Tullo, NG, 1993
)
1.95
"Isradipine is an effective antihypertensive drug with very good tolerance."( [The antihypertensive effect of isradipine and additional pharmacodynamic effects].
Mayer, O; Polívková, H, 1993
)
1.29
"Isradipine (lomir) is a new highly selective arteriolar vasodilator of the dihydropyridine group, characterized by a slight cardiodepressive effect. "( [Lomir in the treatment of arterial hypertension after angioplastic surgery].
Eremenko, AA; Lebedeva, RN; Matiunin, AV; Mikhaĭlov, IuM; Ziuliaeva, TP,
)
1.57
"Isradipine appears to be an effective relaxant in rat myometrium."( Inhibitory effects of isradipine on spontaneous and oxytocin- and carbachol-stimulated contractions of rat myometrium.
Cetin, A; Cetin, M; Kaya, T; Sarioglu, Y, 1998
)
1.34
"rac-Isradipine is a dihydropyridine type calcium antagonist. "( Enantioselective determination of isradipine in human serum using chiral stationary phase liquid chromatography and gas chromatography with nitrogen selective detection.
Angelo, HR; Christensen, HR; Rask, HS, 1998
)
1.14
"Isradipine is a calcium channel blocker of the dihydropyridine class. "( Initial experience with isradipine for the treatment of hypertension in children.
Groshong, T; Strauser, LM; Tobias, JD, 2000
)
2.06
"Isradipine is an effective, orally administered agent for control of hypertension in children."( Initial experience with isradipine for the treatment of hypertension in children.
Groshong, T; Strauser, LM; Tobias, JD, 2000
)
2.06
"Isradipine is a calcium channel-blocking agent of the dihydropyridine type, used in the treatment of hypertension. "( Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?
Angelo, HR; Antonsen, K; Bonde, J; Christensen, HR; Kampmann, JP; Lindekaer, A; Simonsen, K, 2000
)
2.02
"Isradipine is a new dihydropyridine calcium-channel blocker that appears to exert less negative inotropic activity than nifedipine and to selectively inhibit sinoatrial conduction. "( Isradipine--another calcium-channel blocker for the treatment of hypertension and angina.
Lopez, LM; Santiago, TM, 1992
)
3.17
"Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race. "( Isradipine: overall clinical experience in hypertension in the United States.
Miller, H, 1990
)
3.16
"Isradipine is a more potent vasodilator than nifedipine at the same infusion rate."( Effect of isradipine on left ventricular relaxation and diastolic filling.
Hess, OM; Hoppeler, H; Hug, R; Krayenbühl, HP; Turina, J, 1990
)
1.4
"Isradipine is an acceptable agent for the treatment of hypertension in this setting."( Isradipine for treatment of acute hypertension after myocardial revascularization.
Alpern, J; Barnette, RE; Brister, NW; McClurken, JB; Schartel, SA, 1991
)
3.17
"Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race. "( Isradipine: overall clinical experience in hypertension in the United States.
Miller, H, 1991
)
3.17
"Isradipine is a new dihydropyridine calcium antagonist with a high degree of selectivity for the coronary, cerebral, and skeletal muscle vasculature. "( The place of isradipine in the treatment of hypertension.
Man in't Veld, AJ, 1991
)
2.09
"Isradipine is a potent dihydropyridine calcium channel blocker. "( Isradipine.
Schachter, M, 1991
)
3.17
"Isradipine is a dihydropyridine calcium-entry blocking agent with pronounced vasodilator activity and no significant cardiac effects at clinical doses, a desirable profile for an antihypertensive drug. "( A multicenter comparison of isradipine and prazosin for treatment of essential hypertension.
Gonasun, LM; McAllister, RG; Swartz, SL; Thadani, U, 1990
)
2.02
"Isradipine is a calcium antagonist with marked vascular selectivity and, in practical terms, is devoid of cardiac effects."( Isradipine in hypertension.
Hansson, L, 1990
)
2.44
"Isradipine is a new calcium antagonist of the dihydropyridine type, with marked vasodilator activity and minimum negative inotropic effects. "( Multicentre isradipine dose-confirmation study in Thai patients with hypertension.
Charoenlarp, K; Jaroonvesama, N; Koanantakul, B; Nontakanun, S; Tanomsup, S; Tantbirojn, P, 1990
)
2.1
"Isradipine is a new dihydropyridine calcium antagonist that is highly effective in lowering blood pressure."( A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).
Bond, G; Brugger, S; Byington, R; Flack, JM; Grimm, RH, 1990
)
1.21
"Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis."( Efficacy and safety of isradipine in hypertension.
Brockway, B; Carr, AA; Davidov, M; Gonasun, L; Hamilton, B; Hamilton, J; Prisant, LM; Schnaper, H; Shepherd, AM; Velasquez, M, 1989
)
1.31
"Isradipine (PN 200-110) is a new dihydropyridine calcium-entry blocker with powerful vasodilating properties. "( Electrophysiological properties of isradipine (PN200-110) in humans.
Crijns, HJ; Lie, KI; Ruegg, P; van den Toren, WE; van Gelder, I; van Wijk, LM, 1989
)
2
"Isradipine is a new calcium antagonist of the dihydropyridine type with marked vasodilator activity and minimal negative inotropic effects. "( Improved blood pressure control with isradipine in hypertensive patients treated with pindolol.
Aström, B; Dahlöf, B; Frithz, G; Hansson, L; Himanen, P; Sundstedt, CD; Tollin, C, 1989
)
1.99
"Isradipine is a more specific treatment for post-aortocoronary bypass graft hypertension than nitroprusside because its systemic arterial dilating effect is associated with a minimum of other circulatory changes."( Use of isradipine in hypertension following coronary artery bypass surgery.
Davies, SW; Feneck, RO; Lunnon, MW; Underwood, SM; Walesby, RK, 1989
)
1.45
"Isradipine is a new dihydrophyridine calcium antagonist with powerful vasodilating properties. "( Cardiac electrophysiologic properties of intravenous isradipine in patients with sick sinus syndrome.
Crijns, HJ; Lie, KI; Rüegg, PC; van den Toren, EW; van Gelder, I; van Wijk, LM, 1989
)
1.97
"Isradipine is a new potent calcium-channel blocking agent with highly selective action on peripheral vessels. "( The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.
Jonasson, T; Leppert, J; Nilsson, H; Ringqvist, I, 1989
)
2.08
"Isradipine is a new dihydropyridine calcium antagonist with myocardial effects significantly different from those of nifedipine, as shown by in vitro and animal experimental data. "( Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockade in coronary artery disease.
Ickrath, O; Karsch, KR; Mauser, M; Voelker, W, 1989
)
1.96

Effects

Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients.

Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients. The isradipne dose may have been insufficient to engage the target calcium channels associated with neuroprotective effects.

ExcerptReferenceRelevance
"Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients."( Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine.
Frishman, WH, 1994
)
1.22
"Isradipine has a beneficial effect on in-vivo platelet function as evidenced by a decreased platelet deposition on vascular lesion sites and an associated prolonged platelet survival in patients with hypertension and active atherosclerotic lesions."( Effect of isradipine on in-vivo platelet function.
Kritz, H; O'Grady, J; Pirich, C; Schmid, P; Sinzinger, H, 1997
)
1.42
"The isradipine dose may have been insufficient to engage the target calcium channels associated with neuroprotective effects."( Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.
, 2020
)
2.56
"Isradipine has not been systematically studied in patients with Parkinson's disease (PD)."( Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
Avram, MJ; Borushko, E; Martel, A; Miskevics, S; Simuni, T; Surmeier, DJ; Videnovic, A; Weaver, FM; Williams, K; Zadikoff, C, 2010
)
1.43
"Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients."( Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine.
Frishman, WH, 1994
)
1.22
"Isradipine (ISR) has been reported to block cocaine-induced conditioned place preference. "( Isradipine produces neither a conditioned place preference nor aversion.
Calcagnetti, DJ; Schechter, MD, 1994
)
3.17
"Isradipine has less negative exotropic effect than other available calcium antagonists, and generally does not affect cardiac output, stroke volume, or heart rate when used chronically to treat hypertension."( Cardiac effects of isradipine in patients with hypertension.
Lund-Johansen, P, 1993
)
1.34
"Isradipine has been shown to be an effective vasodilator in different vascular beds. "( Isradipine and the coronary circulation.
Feneck, RO; Underwood, SM; Walesby, RK, 1993
)
3.17
"Isradipine has a beneficial effect on in-vivo platelet function as evidenced by a decreased platelet deposition on vascular lesion sites and an associated prolonged platelet survival in patients with hypertension and active atherosclerotic lesions."( Effect of isradipine on in-vivo platelet function.
Kritz, H; O'Grady, J; Pirich, C; Schmid, P; Sinzinger, H, 1997
)
1.42
"Isradipine has favourable effects comparable with those of nifedipine in patients with chronic stable angina and can be safely administered in these patients."( Effects of the calcium antagonist, isradipine, and nifedipine on resting and exercise haemodynamics and the neurohumoral system in patients with stable chronic angina.
Burger, KJ; Kornecki, P; Mitrovic, V; Rieckmann, C; Schlepper, M; Welzel, D, 1990
)
1.28
"Isradipine also has antiatherogenic properties in animal models of atherosclerosis."( A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).
Bond, G; Brugger, S; Byington, R; Flack, JM; Grimm, RH, 1990
)
1.21
"Isradipine has proved to be the most potent and effective calcium antagonist for reducing the infarct size compared with other representatives of this class of drugs such as nimodipine, nicardipine and flunarizine."( Experimental studies with isradipine in stroke.
Rudin, M; Sauter, A, 1990
)
1.3
"Isradipine has no clinically important interaction with digoxin."( Comparative effects of verapamil and isradipine on steady-state digoxin kinetics.
Johnson, BF; Johnson, J; Ritchie, P; Rodin, SM; Wilson, J, 1988
)
1.27

Actions

Isradipine did not produce a significant change in systolic or diastolic blood pressure. Glomerular filtration rate, renal plasma flow, renal vascular resistance, and urinary albumin excretion remained constant.

ExcerptReferenceRelevance
"Isradipine did not produce a significant change in systolic or diastolic blood pressure, and glomerular filtration rate, renal plasma flow, renal vascular resistance, and urinary albumin excretion remained constant."( Renal effects of the new calcium channel blocking drug isradipine.
Burger, KJ; Häussler, M; Krämer, BK; Müller, GA; Ress, KM; Risler, T, 1990
)
1.25
"Isradipine did not produce more laboratory, clinical, or electrocardiographic abnormalities than did placebo."( Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
, 1989
)
1.26
"Isradipine did not produce more laboratory, electrocardiographic, or clinical abnormalities, or adverse events than did placebo."( Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group.
, 1989
)
1.25

Treatment

Pretreatment with isradipine (0, 1.0, 3.0 and 5.0 mg/kg i.p.) resulted in a dose-dependent blockade of ethanol discrimination. Treatment with isRadipine reduced the hypertrophy of smooth muscle cells of the tunica media and the structural impairment of the Tunica intima.

ExcerptReferenceRelevance
"Isradipine treatment significantly improved the verbal memory and attention dysfunction in some variables of the Stroop test, compared with the placebo."( Adjunctive Raloxifene and Isradipine Improve Cognitive Functioning in Patients With Schizophrenia: A Pilot Study.
Armani Kian, A; Esmaeilzadeh, A; Mazloomzadeh, S; Vahdani, B; Yousefi, V; Zenoozian, S,
)
1.15
"Isradipine-treated animals displayed a dose-dependent reduction in L-DOPA-induced rotational behavior and abnormal involuntary movements. "( Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ, 2009
)
1.8
"Both isradipine treatments were equally effective in reducing the mean 24-h BP levels."( Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure.
degli Uberti, EC; Fersini, C; Manfredini, R; Portaluppi, F; Vergnani, L, 1995
)
1.05
"In isradipine-treated patients, 20 hours after reinjection of radiolabeled LDL, the quantitative LDL entry was reduced by at least 4.7% with a maximum of 23.5% (p < 0.01) in type I (n = 50 lesions) or type II lesions (n = 41)."( Evidence for lipid regression in humans in vivo performed by 123iodine-low-density lipoprotein scintiscanning.
Pirich, C; Sinzinger, H, 1995
)
0.81
"Isradipine treatment reduced systolic blood pressure in SHR."( Influence of isradipine treatment on left ventricular and coronary vascular hypertrophy in spontaneously hypertensive rats.
Amenta, F; Ferrante, F, 1994
)
1.38
"On isradipine treatment these parameters remained unchanged."( A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension.
Christensen, P; Feldt-Rasmussen, B; Jensen, T; Nørgaard, K, 1993
)
1.09
"The isradipine treatment arm showed a mean decrease in PD of 0.59 mm at week 8 (P < 0.05)."( Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine.
Bednarczyk, EM; Bissada, NF; Carlson, M; Sheehan, H; Westbrook, P, 1997
)
0.99
"In isradipine-treated groups I/M ratios were significantly decreased (0.15 +/- 0.03, 0.12 +/- 0.02, 0.1 +/- 0.02 for the 0.5, 1 and 4 mg kg-1 day-1 doses respectively)."( Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits.
Donetti, E; Fumagalli, R; Paoletti, R; Soma, MR, 1997
)
1.09
"Isradipine pretreatment generally did not significantly alter the subject-rated or performance-impairing effects of ethanol."( Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans.
Pazzaglia, PJ; Rush, CR, 1998
)
1.36
"Isradipine treatment did not modify the vasodilating effect of sodium nitroprusside."( Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients.
Ceravolo, R; Chello, M; Cuda, G; Iacopino, S; Maio, R; Mastroroberto, P; Mattioli, PL; Perticone, F; Ventura, G, 1999
)
1.35
"Isradipine treatment had no effect on vasoconstrictor responses to norepinephrine in vitro."( Effect of chronic treatment with the calcium entry blocker, isradipine, on vascular calcium overload produced by vitamin D3 and nicotine in rats.
Atkinson, J; Capdeville-Atkinson, C; Chillon, JM; Henrion, D, 1992
)
1.25
"Isradipine treatment significantly inhibited platelet aggregation induced by LDL and serotonin; the amplifying effect of LDL on serotonin-induced aggregation seen with placebo was not observed after 12 weeks of treatment with isradipine."( Serotonin and platelet activation during treatment with isradipine.
Dzurik, R; Fedelesova, V; Fetkovska, N; Sebekova, K, 1991
)
1.25
"Isradipine treatment normalized blood pressure values in SHR and significantly reduced the area occupied by the medial layer and the wall-to-lumen ratio in small and medium-sized, but not in large-sized, coronary artery branches."( Effect of long-term isradipine treatment on the hypertension-dependent changes in coronary arteries in spontaneously hypertensive rats.
Amenta, F; Ferrante, F, 1991
)
1.33
"The isradipine-treated ambulatory hypertensive group experienced significantly greater decreases in BP during 24-hour, work, awake and sleep periods than did the ambulatory normotensive group."( Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure.
Dion, D; Lacourcière, Y; Poirier, L; Provencher, P, 1990
)
1.06
"Treatment with isradipine prevented against MPP+-induced iron influx in the MES23.5 cells."( Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Liu, S; Ma, ZG; Wang, QM; Xu, YY, 2017
)
2.24
"Pretreatment with isradipine (10(-6) M) or indomethacin (10(-7) M), concentrations that themselves had no effect on spontaneous contractility, significantly increased the inhibitor responses to sevoflurane on amplitude and frequency of myometrial contractions, beginning at 1 MAC (P<0.05)."( Interactive effect of sevoflurane with isradipine or indomethacin on spontaneous contractile activity of isolated pregnant rat myometrium.
Bagcivan, I; Gursoy, S; Kafali, H; Karadas, B; Kaya, T; Kunt, N, 2004
)
0.92
"Pretreatment with isradipine (0, 1.0, 3.0 and 5.0 mg/kg i.p.) resulted in a dose-dependent blockade of ethanol discrimination."( Blockade of ethanol discrimination by isradipine.
Agabio, R; Colombo, G; Fadda, F; Gessa, GL; Lobina, C; Reali, R, 1994
)
0.88
"Treatment with isradipine reduced the hypertrophy of smooth muscle cells of the tunica media and the structural impairment of the tunica intima."( Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats.
Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1994
)
1
"Pretreatment with isradipine attenuated ET-1-induced contraction by 26% at 3 x 10(-4) mol/L and by up to 80% at 10(-3) mol/L."( Effects of isradipine on endothelin-induced constriction of myometrial arteries in normotensive pregnant women.
Kublickas, M; Kublickiene, KR; Lindblom, B; Lunell, NO; Nisell, H; Wolff, K, 1994
)
1
"Treatment with isradipine alone caused a sustained reduction in blood pressure (-22/-10 mm Hg, P < 0.01), but an increase in body weight (+2.2 kg, P < 0.05) and HbA1c (+1.5%; P < 0.001) were also noted. "( Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Berne, C; Lind, L; Lithell, H; Pollare, T, 1994
)
0.96
"Treatment with isradipine significantly improved the morphology of the endothelium in SHR."( Structural changes in the endothelium of the femoral artery of spontaneously hypertensive rats: sensitivity to isradipine treatment.
Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1993
)
0.84
"Treatment with isradipine plus either spirapril or pindolol was discontinued in 32 patients (5.4%) because of side-effects related, or possibly related, to the study treatment."( Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS).
Magometschnigg, D, 1993
)
2.07
"Treatment with isradipine SRO 5 mg/day administered between 8 and 9 AM was started."( Analysis of blood pressure rhythms for drug efficacy evaluation.
Angotti, S; Bravo, S; Codispoti, P; Damiani, S; Federico, L; Germanò, G; Muscolo, M, 1996
)
0.63
"Pre-treatment with isradipine significantly reduced some of these positive subjective effects and craving for d-methamphetamine."( Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study.
Ait-Daoud, N; Bordnick, PS; Johnson, BA; Roache, JD, 1999
)
2.07
"Treatment with isradipine reduced systolic and diastolic blood pressures significantly at rest."( Effect of isradipine on responses to standardized physical stress tests in hypertension of pregnancy.
Grunewald, C; Lunell, NO; Nisell, H, 1992
)
1.03
"Treatment with isradipine resulted in a substantial reduction in blood pressure due to a reduction in peripheral resistance."( Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria.
Andersson, OK; Hedner, T; Karlberg, B; Persson, B; Wysocki, M, 1992
)
0.62
"Treatment with isradipine lowered blood pressure and improved red blood cell filterability (P less than .05) compared with placebo."( Effect of isradipine on factors affecting blood viscosity.
Cristal, N; Paran, E; Slonim, A, 1991
)
1.02

Toxicity

Isradipine did not produce more laboratory, electrocardiographic, or clinical abnormalities, or adverse events than did placebo. The most frequently reported adverse reactions were headache, dizziness, and edema in the isradipne group. cough, headache, and chest pain in the enalapril group.

ExcerptReferenceRelevance
"Nowadays, physicochemical approach to understanding toxic effects remains underdeveloped."( Variability of fluorescence spectra of coelenteramide-containing proteins as a basis for toxicity monitoring.
Alieva, RR; Kudryasheva, NS, 2017
)
0.46
"5mg twice daily is effective, safe and tolerable in mild to moderate hypertension."( Efficacy, tolerability and safety of isradipine (Lomir) in the treatment of mild to moderate Tanzanian hypertensives.
Lwakatare, JM; Maro, EE; Mtulia, IA, 1992
)
0.56
" The most frequently reported adverse reactions were headache, dizziness, and edema in the isradipine group, and cough, headache, and chest pain in the enalapril group."( A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension.
Eisner, GM; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR; Vargas, R; Zemel, M, 1991
)
0.75
" Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects."( Efficacy and safety of isradipine in hypertension.
Brockway, B; Carr, AA; Davidov, M; Gonasun, L; Hamilton, B; Hamilton, J; Prisant, LM; Schnaper, H; Shepherd, AM; Velasquez, M, 1989
)
0.59
" Adverse events were usually mild, transient, and typical for vasodilators."( Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
, 1989
)
0.54
" The blood pressure-lowering effect of isradipine as monotherapy is dose dependent and has shown a greater efficacy than propranolol, hydrochlorothiazide, and prazosin, without an increase in adverse effects."( Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension.
Dahlöf, B, 1989
)
0.8
" Isradipine did not produce more laboratory, electrocardiographic, or clinical abnormalities, or adverse events than did placebo."( Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group.
, 1989
)
1.44
" Overall, 242 patients (40 percent) reported adverse events, 39 (7 percent) of whom withdrew from the study for this reason."( A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension.
Keller, A; Rüegg, PC; Sundstedt, CD; Waite, R, 1989
)
0.51
" The side-effect score for edema was lower with ISR plus diuretics than with other combinations, whereas the ACE inhibitor was associated with a higher score for cough."( Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial.
Lüscher, TF; Waeber, B, 1993
)
0.29
" This requires that the antihypertensive agent chosen have a demonstrated safe profile."( Antihypertensive therapy with isradipine in patients with special safety concerns.
Blecker, D, 1994
)
0.58
" A total of 629 patients (19%) reported adverse events, 79 (2."( Efficacy, safety, and tolerability of isradipine in hypertension as used in general practice in a developing country (Pakistan).
Hashmi, MS; Khan, AH; Samad, A, 1993
)
0.56
" Nineteen patients experienced 43 adverse events, most of which were rated mild to moderate."( [Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study].
Burger, KJ; Dehner, R, 1996
)
0.55
"A meta-analysis was performed to compare the risk of serious adverse events associated with the use of all formulations of isradipine, when used as monotherapy in hypertension, to active drug or placebo controls."( Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis.
Allen, IE; Arellano, FM; Kumashiro, M; Kupelnick, B; Mohanty, N; Ross, SD, 1997
)
0.74
" No serious adverse events were reported."( Safety and efficacy of therapeutically equivalent doses of sustained-release formulations of isradipine and felodipine.
Ganz, MB; Saska, BA,
)
0.35
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The most common adverse events were peripheral edema (30) and dizziness (24)."( Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
, 2013
)
0.63

Pharmacokinetics

The pharmacokinetic variables and antihypertensive effect of the calcium antagonist isradipine, were investigated in 30 hypertensive patients. A terminal half-life of 8-9 hr has been reported.

ExcerptReferenceRelevance
" Area under the blood concentration-time curve (AUC), the maximum blood concentration (Cmax) and the time to reach Cmax (Tmax) on D-1 and D+13 were not significantly different whatever the specificity of the RIA method."( Lack of effect of isradipine on cyclosporin pharmacokinetics.
Bourbigot, B; Codet, JP; Le Saux, L; Moal, MC; Morin, JF; Vernillet, L, 1992
)
0.62
"Drug level monitoring during routine clinical visits in the course of phase III trials provides a means to document pharmacokinetic variability in a patient population."( Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine.
Fertil, B; Jais, JP; Laplanche, R; Niederberger, W; Nüesch, E; Steimer, JL, 1991
)
0.5
"1) increase in peripheral volume of distribution contributed to prolonged elimination half-life (23."( The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics.
Hoch, K; Johnson, BF; Johnson, J; Marwaha, R; Wilson, J, 1987
)
0.27
" Repeated administration of [14C]PN 200-110 showed no change in pharmacokinetic characteristics."( Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.
Jaffe, JM; Tse, FL, 1987
)
0.56
"We have examined the pharmacokinetic interaction between isradipine and lovastatin in six male and six female, healthy, normotensive, human subjects after a single dose and after treatment for 5 days."( Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers.
Finley, DK; Hassell, AE; Holtzman, JL; Zhou, LX, 1995
)
0.81
"The pharmacokinetic variables and antihypertensive effect of the calcium antagonist isradipine, were investigated in 30 hypertensive patients."( Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients.
Christensen, HR; Kampmann, JP; Simonsen, K, 1993
)
0.75
" isradipine to assess a possible pharmacokinetic interaction."( Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers.
Blom, M; Grass, P; Kovarik, JM; Kutz, K; Meyer, EC; Ott, S; Snyman, JR; Sommers, DK; van Wyk, M, 1993
)
1.5
" A terminal half-life of 8-9 hr has been reported, in several pharmacokinetic studies after oral administration of isradipine."( Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?
Angelo, HR; Antonsen, K; Bonde, J; Christensen, HR; Kampmann, JP; Lindekaer, A; Simonsen, K, 2000
)
0.78
"There was very little significant difference between SAMR1 and SAMP8 in terms of the half-life (t(1/2)), total body clearance (CL(tot)), steady-state volume of distribution (Vd(ss))."( In vivo specific binding characteristics and pharmacokinetics of a 1,4-dihydropyridine calcium channel antagonist in the senescent mouse brain.
Deguchi, Y; Kimura, R; Uchida, S; Yamada, S; Yamamoto, M, 2000
)
0.31
"It was established that a regular administration of isradipine is accompanied by an increase in the mean values of Cmax (by 21."( [Pharmacokinetic and pharmacodynamic effects of isradipine in patients with arterial hypertension].
Alekhin, SN; Svetyĭ, LI,
)
0.64
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" This method offered good precision and accuracy and was successfully applied for the pharmacokinetic and bioequivalence studies of 5 mg of sustained-release isradipine in 24 healthy Korean volunteers."( Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study.
Jhee, OH; Kang, JS; Kim, SH; Lee, MH; Park, JH; Park, YS; Rhim, SY; Shaw, LM; Yang, SC, 2009
)
0.88
" The pharmacokinetic parameters were evaluated in male albino Wistar rats, and a significant improvement in bioavailability (2."( Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery.
Bobbala, SK; Veerareddy, PR, 2012
)
0.63
"Plasma samples from nearly all study participants randomized to immediate-release isradipine 5-mg twice daily (166 of 170) were collected for population pharmacokinetic modeling."( Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
James Surmeier, D; Javidnia, M; Oakes, D; Simuni, T; Venuto, CS; Yang, L, 2021
)
2.29

Compound-Compound Interactions

Isradipine is superior to methyldopa and, whether as monotherapy or in combination with captopril, highly effective and well tolerated in the treatment of mild-to-moderate hypertension.

ExcerptReferenceRelevance
"The antihypertensive effect and safety of treatment of hypertension with isradipine, a Ca antagonist of dihydropyridine group in monotherapy and in combination with the betablocker bopindolol was assessed in a multicentre study joined by six Czechoslovak centres."( Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives.
Dvorák, I; Dzúrik, R; Fetkovská, N; Jonás, P; Kotlík, I; Markuljak, I; Petr, P; Widimský, J, 1990
)
1.95
" The combination of captopril and isradipine was more effective than captopril given with a low dose of hydrochlorothiazide."( Additive effect of isradipine in combination with captopril in hypertensive patients.
Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1989
)
0.88
" In conclusion, treatment with dihydropyridines alone or in combination with low-dose aspirin can prevent circadian increases in platelet activity in patients with essential hypertension."( Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension.
Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L, 1994
)
0.29
"To evaluate the effects of isradipine alone and in combination with pindolol on glucose and lipid metabolism during long-term antihypertensive therapy."( Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Berne, C; Lind, L; Lithell, H; Pollare, T, 1994
)
0.9
" When isradipine was combined with pindolol there was also a reduction in insulin sensitivity and an increase in VLDL triglycerides, possibly as effects of the beta-adrenergic blockade."( Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Berne, C; Lind, L; Lithell, H; Pollare, T, 1994
)
1.09
" These results indicate that isradipine is superior to methyldopa and, whether as monotherapy or in combination with captopril, highly effective and well tolerated in the treatment of mild-to-moderate hypertension."( A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.
Cristal, N; Yodfat, Y, 1993
)
0.81
"001) than patients treated with any of the monotherapies or with methyldopa in combination with captopril."( Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.
Amir, M; Bar-On, D; Cristal, N; Yodfat, Y, 1996
)
0.52
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

Isradipine (ID), is an antihypertensive drug, having low oral bioavailability (15-24%) due to poor aqueous solubility. The bioavailability of SRO was increased by less than 20% compared with the same daily dose given as NR, indicating that the two forms are bioequivalent.

ExcerptReferenceRelevance
"The bioavailability of isradipine has been examined in 7- and 52-week-old rats after oral (12."( Bioavailability of isradipine in young and old rats: effect of mode of administration.
Hassell, AE; Jaffe, JM; Schran, HF; Tse, FL, 1989
)
0.92
" PN 200-110 was rapidly and almost completely (90-95%) absorbed from the gastrointestinal tract, although the estimated bioavailability was only 17% due to extensive first-pass metabolism."( Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.
Jaffe, JM; Tse, FL, 1987
)
0.56
"The pharmacokinetics and relative bioavailability of oral isradipine, a dihydropyridine calcium channel blocking agent, were determined in 42 normal male volunteers participating in two separate studies."( The pharmacokinetics of oral isradipine in normal volunteers.
Blouin, RA; Clifton, GD; Dilea, C; Foster, TS; Gonasun, LM; Hassell, AE; Schran, HF, 1988
)
0.81
" Rate, but not extent of bioavailability differs between the two isradipine formulations."( Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients.
Christensen, HR; Kampmann, JP; Simonsen, K, 1993
)
0.76
" In comparison with the standard formulation, the absolute bioavailability of the sustained-release preparation is somewhat increased at about 22."( [Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies].
Hirschberger, R, 1993
)
0.53
" The bioavailability of SRO was increased by less than 20% compared with the same daily dose given as NR, indicating that the two forms are bioequivalent and that no adjustment in the total daily dose of isradipine is necessary when switching from one form to the other."( Bioequivalence of a slow-release and a non-retard formulation of isradipine.
Holmes, DG; Kutz, K, 1993
)
0.71
" With calcium antagonists in particular, an assessment of the rate of absorption and of the maximum concentration is important, as those characteristics may have implications for the safety profile with this class of drugs."( Bioequivalence of controlled-release calcium antagonists.
Luus, HG; Müller, FO; Müller, FR; Schall, R, 1997
)
0.3
" Breath-alcohol levels were significantly lower after isradipine pretreatment, which suggests isradipine altered the bioavailability of ethanol."( Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans.
Pazzaglia, PJ; Rush, CR, 1998
)
0.88
" The bioavailability was estimated as well."( Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?
Angelo, HR; Antonsen, K; Bonde, J; Christensen, HR; Kampmann, JP; Lindekaer, A; Simonsen, K, 2000
)
0.57
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The relative bioavailability of the SR formulation was 55."( Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals.
Ait-Daoud, N; Javors, MA; Johnson, BA; Lam, YW; Lawson, K; Roache, JD; Tiouririne, M; Wells, LT, 2005
)
0.57
" It undergoes extensive first pass metabolism and bioavailability through the oral route is only about 15 to 24%."( Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics.
Gannu, R; Jangala, VR; Khagga, M; Tirunagari, M, 2010
)
0.64
" With the goal of determining if there is sufficient experimental support to move forward with animal trials of isradipine, we determined its bioavailability in the triple transgenic mouse model of AD."( L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease.
Anekonda, TS; Frahler, K; Harris, C; Quinn, JF; Wadsworth, TL; Woltjer, RL, 2011
)
0.83
"Proliposomes loaded with isradipine were prepared successfully to enhance the oral bioavailability of isradipine."( Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery.
Bobbala, SK; Veerareddy, PR, 2012
)
0.94
"The objective of the present research was to develop a proniosomal formulation of isradipine and to evaluate the influence of proniosomal systems on the oral bioavailability of the drug in albino Wistar rats."( Enhanced oral bioavailability of isradipine via proniosomal systems.
Bobbala, SK; Veerareddy, PR, 2013
)
0.9
" The dissolution behaviors and in vivo bioavailability of controlled release matrix tablet in healthy human volunteers were investigated."( Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion.
Lee, BJ; Lim, J; Oh, KT; Park, JB; Piao, ZZ; Rhee, YS; Tran, PH; Tran, TT; Vo, TV, 2013
)
0.62
"Isradipine (ISR) is a potent calcium channel blocker with low oral bioavailability due to low aqueous solubility, extensive first-pass metabolism and P-glycoprotein (P-gp)-mediated efflux transport."( Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
Bandari, S; Eedara, BB; Jukanti, R; Kandadi, P; Ramasahayam, B, 2015
)
2.21
"Isradipine (ID), is an antihypertensive drug, having low oral bioavailability (15-24%) due to poor aqueous solubility (0."( Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Narendar, D; Swetha, E; Thirupathi, G, 2017
)
2.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The objective of the present paper is to formulate nanostructured lipid carriers (NLCs) of a calcium channel blocker, isradipine, to enhance its oral bioavailability and prolong its antihypertensive effect apart from evaluating efficacy of the formulation in isoproterenol induced myocardial infarction in rats."( Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction.
Alam, T; Ali, J; Ansari, MA; Baboota, S, 2022
)
1.21

Dosage Studied

Isradipine inhibited the dose-response curves of norepinephrine on the blood pressure in 6- and 40-week-old animals more effectively than those in 10-week old animals. No clear-cut dosing regimen alterations, based on single-dose data, are warranted in renal impairment.

ExcerptRelevanceReference
" The patients were divided in three groups according to the used dosage of Isradipine tablets by sublingual route."( [Treatment of hypertensive crisis in outpatients with sublingual isradipine].
Lotaif, LD; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Ventura, RP, 1992
)
0.75
" If normalization of diastolic blood pressure (BP) had not been reached, the dosage was increased to 5 mg."( MIS (Multicentric Isradipine Study of antihypertensive therapy).
Balazovjech, I; Dzúrik, R; Fetkovská, N; Kvasnicka, J; Lupínek, Z; Mayer, O; Pidrman, V; Widimský, J, 1992
)
0.62
" A double-dummy technique was used to maintain blindness and no dosage titration was made."( Clinical equivalence of once-daily administration of a modified-release formulation of isradipine and twice-daily administration of the standard formulation. Multicentre Study Group.
Holmes, D; Moullet, C, 1992
)
0.51
" No dose-dependent reductions in blood pressure were observed with the dosage range employed in this study."( Isradipine in the treatment of hypertensive crisis in ambulatory patients.
Lotaif, L; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Ventura, RP, 1992
)
1.73
"Analysis of an antihypertensive drug trial, which involved measurements of blood pressure (BP) during visits to the clinic at a set time of day, showed that the initial dosage titration procedure had been inadequate in some patients."( Timing of blood pressure measurements in determining anomalies in duration of effect of an antihypertensive drug: assessment of isradipine.
Boutagy, J; Dunagan, F; Johnston, HJ; Marwood, JF; Shenfield, GM; Stokes, GS, 1990
)
0.48
"The objectives of this study were (a) to evaluate the dose-response effect of isradipine, a dihydropyridine calcium antagonist, on the heart rate and blood pressure of males with mild to moderate hypertension; and (b) to compare these results with those obtained with propranolol, a beta-adrenoceptor blocker, on a matched patient population."( Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
Cantor, A; Cristal, N, 1990
)
0.72
" Nevertheless, experiments in atherosclerotic animals indicate that the dose has to be chosen more cautiously than for young animals, as the dose-response curve for several effects is bell-shaped."( Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
Hof, RP; Rüegg, UT, 1991
)
0.51
" Dose-response curves reveal that isradipine is one of the most potent and efficacious representatives of this class of compounds, reducing the infarct size by more than 60%."( Prevention of stroke and brain damage with calcium antagonists in animals.
Rudin, M; Sauter, A, 1991
)
0.56
"The objective of this study was to compare the effects of isradipine and placebo on blood pressure (BP) at the end of the dosing interval ('trough')."( Isradipine twice daily lowers blood pressure over 24 H.
de Zwart, P; Holmes, DG; Lasance, A; Man in't Veld, AJ, 1991
)
1.97
" The Montevideo Mathematical Model was used to determine the time course of the response to treatment in each dosage group."( Time course of the blood pressure response to oral isradipine in uncomplicated mild-to-moderate essential hypertension.
Leary, WP; Maharaj, B; Reyes, AJ; van der Byl, K, 1991
)
0.53
" Dosage was titrated for six weeks on the basis of blood pressure (BP) response and was then maintained for the remainder of the study."( A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension.
Eisner, GM; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR; Vargas, R; Zemel, M, 1991
)
0.53
" Both treatments resulted in satisfactory BP reduction during 24 hours (daily reduction of 4/6 and 12/9 mmHg twice daily and once daily dosing respectively)."( A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients.
Christensen, HR; Kampmann, JP; Simonsen, K, 1991
)
0.58
"The role of calcium in drug-induced contractions of rat gastric fundus strips was evaluated by determining the effect of two procedures on the dose-response curves of agonists: a) removal of calcium from the nutrient solution and b) blockade of calcium channels with the dihydropyridine isradipine."( Comparison of the effect of calcium withdrawal from the medium and of blockade of extracellular calcium entry by isradipine on the contractile responses of the isolated rat stomach.
Garcia, AG; Jurkiewicz, A; Jurkiewicz, NH; Smaili, SS, 1991
)
0.67
" In this dosage peripheral effects--decrease of peripheral vascular resistance and mean aortic pressure--did not differ significantly between them."( [Myocardial effects of the calcium antagonists nifedipine, nisoldipine and isradipine in coronary heart disease].
Ickrath, O; Karsch, KR; Kühlkamp, V; Mauser, M; Voelker, W, 1990
)
0.51
"The efficacy and safety of once-daily dosing of isradipine, a new calcium antagonist vasodilator, was evaluated in a multicenter, placebo-controlled trial in hypertensive patients who had supine diastolic blood pressure (SDBP) 100-119 mm Hg."( Placebo-controlled trial of once-a-day isradipine monotherapy in mild to moderately severe hypertension.
Canosa, FL; Carr, AA; Cohen, M; Kirkendall, WM; Lewin, AJ; McMahon, FG; Winer, N, 1990
)
0.8
" Thus, it is concluded that isradipine, administered in an equally effective antihypertensive dosage regimen is superior to nifedipine with regard to the incidence of adverse effects, resulting in greater patient satisfaction with treatment."( The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine.
Burger, KJ; Welzel, D, 1990
)
0.88
" There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP)."( Efficacy and safety of isradipine in hypertension.
Brockway, B; Carr, AA; Davidov, M; Gonasun, L; Hamilton, B; Hamilton, J; Prisant, LM; Schnaper, H; Shepherd, AM; Velasquez, M, 1989
)
0.83
" Dosage step-up was at three-week intervals."( Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
, 1989
)
0.54
" Using this model, dose-response curves for infarct size, measured by magnetic resonance imaging, and biochemical markers of infarction were obtained for various calcium antagonists."( Cerebrovascular, biochemical, and cytoprotective effects of isradipine in laboratory animals.
Hof, RP; Rudin, M; Sauter, A; Wiederhold, KH, 1989
)
0.52
" In rats, the dose-response curves for pressor effects to angiotensin II were shifted in parallel to the right after treatment with isradipine, but not with prazosin and dihydralazine, suggesting that the antivasoconstrictor effect of isradipine was of a specific type."( Antivasoconstrictor effects of isradipine. A quantitative approach in anesthetized rats and conscious rabbits.
Hof, RP; Rüegg, UT, 1989
)
0.77
"Based on pooled data from three randomized placebo-controlled dose-finding studies in a total of 489 patients, the dose-response relationship for efficacy and adverse events was estimated, using the Michaelis-Menten equation: Effect = maximal effect multiplied by dose/constant plus dose."( Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension.
Simonsen, K; Sundstedt, CD, 1989
)
0.51
" Dose-response comparisons against nifedipine in 21 patients and against isosorbide dinitrate in 14 patients demonstrate that PN 200-110 has a similar antianginal efficacy profile to both drugs."( Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris.
Allen, J; Jackson, NC; Pool, PE; Taylor, SH, 1987
)
0.53
" Dose-response curves were obtained with 4 doses of each drug in 6 animals."( Comparison of cardiodepressant and vasodilator effects of PN 200-110 (isradipine), nifedipine and diltiazem in anesthetized rabbits.
Hof, RP, 1987
)
0.51
" Dose-response curves to acetylcholine (ACh), noradrenaline (NA), phenylephrine (Phen) and angiotensin II (AII), were obtained in 6 cholesterol-fed and 6 control rabbits before and after isradipine (code name PN200-110) 100 micrograms kg-1."( Vasoconstrictor and vasodilator effects in normal and atherosclerotic conscious rabbits.
Hof, A; Hof, RP, 1988
)
0.47
" Considering the interpatient variability in isradipine disposition and the lack of significant differences in CLo between groups, no clear-cut dosing regimen alterations, based on single-dose data, are warranted in renal impairment."( The effects of renal function on the disposition of isradipine.
Blouin, RA; Chandler, MH; Cutler, RE; Gonasun, LM; Schran, HF; Smith, AJ, 1988
)
0.79
" During isradipine therapy, treadmill exercise time 3 hours after dosing was greater than with placebo therapy (P1 312 +/- 23."( Efficacy of the calcium antagonist isradipine in angina pectoris.
Bernstein, V; Enjalbert, M; Parker, JO, 1988
)
0.99
"Continuous nitroglycerin (NTG) administration causes pharmacologic tolerance in humans and animals, whereas intermittent dosing is capable of avoiding or reducing tolerance development."( Continuous versus intermittent nitroglycerin administration in experimental heart failure: vascular relaxation and radioligand binding to adrenoceptors and ion channels.
Bauer, JA; Fung, HL; Gopalakrishnan, M; Kwon, YW; Triggle, DJ; Zheng, W, 1993
)
0.29
" Compliance tends to fall as dosing frequency rises above once daily."( Partial compliance: implications for clinical practice.
Rudd, P, 1993
)
0.29
" A sustained-release oral formulation (SRO) of isradipine was used, and the possible differences in the response to morning nu evening dosing were also investigated."( Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure.
degli Uberti, EC; Fersini, C; Manfredini, R; Portaluppi, F; Vergnani, L, 1995
)
0.85
" The dosage was increased if the average sitting diastolic blood pressure was > 90 mm Hg."( A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension.
Eisner, GM; Jain, AK; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR, 1995
)
0.54
" It is metabolized in the liver and dosage adjustments may not be necessary when administered to patients with renal insufficiency."( Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine.
Frishman, WH, 1994
)
0.5
"ISR and DIL, at the above dosage have showed an important and significant anti-ischemic effect (IT = +41."( [Isradipine versus diltiazem in the treatment of stable effort angina pectoris: ergometric evaluation in a crossover double-blind study].
Borelli, DA; Caristo, S; Costa, R; Maio, R; Mattioli, PL; Perticone, F; Pugliese, F; Torchia, L, 1994
)
1.2
" Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs."( At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.
De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994
)
0.61
" The dosage was titrated if necessary after 4 weeks of treatment."( Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension.
Chan, TY; Critchley, JA; Or, KK; Sanderson, JE; Tomlinson, B; Woo, J, 1994
)
0.62
" If, after 4 weeks of treatment, CR-determined diastolic blood pressure (DBP) was still > 90 mm Hg, this dosage was doubled (n = 327) and, at week 8, pindolol at 5 mg or spirapril at 3 mg daily was added if necessary for blood pressure control."( A multicenter study using causal readings, self-recordings, and ambulatory blood pressure monitoring to assess isradipine effects. AMICUS Study Group.
Fitscha, P; Magometschnigg, D; Meisner, W, 1994
)
0.5
"To determine the appropriate dosage regimen of isradipine in black patients with severe hypertension of pregnancy, 10 patients (gestational age, 30 to 38 weeks; diastolic blood pressure [DBP], 110 to 148 mm Hg; no hypertensive crises; and normal central venous pressure) were given an isradipine infusion while the fetal heart rate was continuously recorded using a cardiotocograph."( Intravenous isradipine in the management of severe hypertension in pregnant and nonpregnant patients. A pilot study.
Khedun, SM; Madhanpall, N; Maharaj, B; Moodley, J; van der Byl, K, 1994
)
0.92
" In clinical trials, monotherapy with the calcium channel blocker (CCB) isradipine (ISR) at a recommended therapeutic dosage has controlled blood pressure with an excellent level of safety."( Antihypertensive therapy with isradipine in patients with special safety concerns.
Blecker, D, 1994
)
0.81
" This pilot study was conducted to determine the appropriate dosage regimen for isradipine in black patients with severe hypertensive disorders of pregnancy."( Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study.
Khedun, SM; Madhanpall, N; Maharaj, B; Moodley, J; van der Byl, K, 1994
)
0.89
" At therapeutic dosage isradipine does not accumulate."( [Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies].
Hirschberger, R, 1993
)
0.84
" During maintenance, patients not at goal were "stepped up," and patients with uncontrolled DBP at maximum dosage were removed from the study."( Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994
)
0.54
" Symptom frequency differed little among the three dosage levels, becoming maximal by the second visit at the same dosage level."( Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994
)
0.54
" Absolute DBP decrements versus placebo peaked 6 h after dosing (-8."( Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study.
Arzilli, F; Borgnino, C; Caiazza, A; Del Prato, C; Gandolfi, E; Ghisoni, F; Giuntoli, F; Innocenti, P; Ponzanelli, F; Saba, P, 1993
)
0.53
"The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed."( Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Symes, LR; Walton, T, 1993
)
0.85
" The results of this study indicated that monotherapy with isradipine SRO at the recommended initial dosage of 5 mg once daily is appropriate in black patients with hypertension."( A comparative study of isradipine SRO and enalapril in black patients with mild-to-moderate hypertension.
Maharaj, B; van der Byl, K, 1993
)
0.84
" Both agents were able to achieve reductions in MAP to 80-90 mmHg quickly and safely, although the effects of isradipine at the dosage used were apparent sooner and gave smoother control than with sodium nitroprusside."( Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery.
Chan, E; De Lange, S; Lawrence, CJ; Lestrade, A, 1993
)
0.82
"9 years), at the dosage of 5 mg once a day."( [Metabolic tolerance of isradipine. Evaluation after three months of therapy].
Bernardini, A; Capone, A; Panuccio, D; Trabatti, MR, 1995
)
0.6
" In anesthetized rats, isradipine inhibited the dose-response curves of norepinephrine on the blood pressure in 6- and 40-week-old animals more effectively than those in 10-week-old animals."( [Age-related alteration of inhibitory effects of isradipine on alpha 1-adrenoceptor mediated responses].
Ashikawa, N; Kanai, S; Satoh, M, 1996
)
0.86
"To evaluate the dosage and effectiveness of isradipine to control acute or chronic hypertension in pediatric patients."( Isradipine therapy in hypertensive pediatric patients.
Jacobson, PA; Johnson, CE; Song, MH, 1997
)
2
"Patient age, gender, weight, disease states, current medications, isradipine dosage and formulation, pre- and postsystolic, and pre- and postdiastolic blood pressure measurements with each dose of isradipine."( Isradipine therapy in hypertensive pediatric patients.
Jacobson, PA; Johnson, CE; Song, MH, 1997
)
1.98
" No change in functional deficit was seen with isradipine with either dosing paradigm at 24 h post-MCA occlusion."( Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.
Campbell, CA; Hadingham, SJ; Hamilton, TC; King, PD; Mackay, KB; Patel, S; Stretton, JL, 1997
)
0.94
" In patients whose blood pressure was not normalized (defined as DBP< or =90 mmHg) after 6 weeks of treatment, the dosage of either medication was doubled or, in the placebo group, was switched to the fixed combination."( Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension.
Antlsperger, A; Pittrow, DB; Schardt, W; Wambach, G; Weidinger, G; Welzel, D, 1997
)
0.53
" In a separate experiment, animals were dosed as described above and were sacrificed by decapitation after the 30-minute treatment period."( Calcium channel antagonist isradipine attenuates cocaine-induced motor activity in rats: correlation with brain monoamine levels.
Ali, SF; Arsah, TA; Mills, K; Shockley, DC, 1998
)
0.6
" After optimal time of release of inhibitor was determined, a dose-response experiment was performed with the competitive binding assay."( Human fetal membranes release a Ca++ channel inhibitor.
Collins, PL; Emery, SP; Idriss, E; Richmonds, C, 1998
)
0.3
" In this article, we show that the effect of verapamil and diltiazem on cyclosporine levels appears to be independent of dosage within their usual prescription range."( Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil.
Chan, L; Jacob, LP; Malhotra, D; Shapiro, JI, 1999
)
0.3
" Because of the lack of specificity of ibotenic acid for a glutamate receptor subtype, a dose-response study with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate was undertaken and calcified areas (identified with Alizarin Red staining) as well as astro- and microglial reactions (by autoradiography with [3H]lazabemide and [3H]Ro 5-4864) were quantified at one month post-lesion."( Long-term effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione in the rat basal ganglia: calcification, changes in glutamate receptors and glial reactions.
Cummins, DJ; Dewar, D; Dragunow, M; Mahy, N; Petegnief, V; Saura, J, 1999
)
0.3
") was administered prior to a cumulative DZP or PCP dose-response determination."( Modulation of the ethanol-like discriminative stimulus effects of diazepam and phencyclidine by L-type voltage-gated calcium-channel ligands in rats.
Grant, KA; Green-Jordan, K, 2000
)
0.31
" Daily dosing clearly is effective in reducing intakes, and suspension of dosing leads to higher intakes."( Research with rats germane to medication for alcoholism: consequences of noncompliance.
Boedeker, KL; Douglass, AV; Hubbell, CL; Reid, LD; Reid, ML, 2001
)
0.31
" This information could be used to design a rational dosage regimen for additional isradipine clinical trials in the treatment of stimulant dependence and related neurovascular disorders."( Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals.
Ait-Daoud, N; Javors, MA; Johnson, BA; Lam, YW; Lawson, K; Roache, JD; Tiouririne, M; Wells, LT, 2005
)
0.8
" CCAs can be safely used in children with renal insufficiency or failure and as a general rule there is no need to modify drug dosage in this population."( A review of calcium channel antagonists in the treatment of pediatric hypertension.
Sahney, S, 2006
)
0.33
" Practically identical isradipine dose-response neuroprotection curves were observed for both measurement procedures."( Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine.
Barone, FC; Chandra, S; Lenhard, SC; Price, WJ; Strittmatter, R; White, RF, 2008
)
0.87
" Artificial neural network technique can be particularly suitable in the pharmaceutical technology of controlled release dosage forms where systems are complex and nonlinear relationships between independent and dependent variables often exist."( Design porosity osmotic tablet for delivering low and pH-dependent soluble drug using an artificial neural network.
Mehta, T; Patel, A; Patel, K; Patel, M; Patel, N, 2012
)
0.38
" A combined method of solid dispersion and controlled release technology could provide versatile dosage formulations containing IDP with poor water solubility and short half-life."( Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion.
Lee, BJ; Lim, J; Oh, KT; Park, JB; Piao, ZZ; Rhee, YS; Tran, PH; Tran, TT; Vo, TV, 2013
)
0.62
"27 h for all dosage groups."( Pharmacokinetic properties of isradipine after single-dose and multiple-dose oral administration in Chinese volunteers: a randomized, open-label, parallel-group phase I study.
Jiang, X; Jin, Z; Wang, L; Wang, Y; Wang, Z, 2013
)
0.68
" To establish a dosage of isradipine controlled-release (CR) that is tolerable and demonstrates preliminary efficacy for use in a future pivotal efficacy trial a Phase 2, randomized, double-blind, parallel group trial (Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease [STEADY-PD]) was undertaken in subjects with early PD not requiring dopaminergic therapy (dopamine agonists or levodopa) randomized 1:1:1:1 to 5, 10, or 20 mg of isradipine CR or matching placebo daily."( Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
, 2013
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
oxidized luciferinsnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
pyrazines
benzoxadiazole
isopropyl esterAny carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
dihydropyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Isradipine Action Pathway478

Protein Targets (63)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
glp-1 receptor, partialHomo sapiens (human)Potency1.99530.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.88320.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency23.98340.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency6.47110.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency28.60080.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency26.60320.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency11.07810.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency2.37100.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.38030.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency28.14370.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.74130.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.12340.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.67450.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency1.11230.005428.02631,258.9301AID1346982; AID1346985
GVesicular stomatitis virusPotency0.38900.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency26.83250.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency3.20130.000723.06741,258.9301AID743085
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency10.00000.10009.191631.6228AID1346983
cytochrome P450 2C19 precursorHomo sapiens (human)Potency19.95260.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency19.95260.00636.904339.8107AID883
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.03980.000323.4451159.6830AID743065; AID743067
importin subunit beta-1 isoform 1Homo sapiens (human)Potency2.31095.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency2.31095.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency2.31095.804816.996225.9290AID540253
gemininHomo sapiens (human)Potency14.66200.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency2.06230.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.38900.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency19.95260.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency3.54810.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.38900.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.38900.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Renilla-luciferin 2-monooxygenaseRenilla reniformis (sea pansy)Ki0.02000.02000.02000.0200AID977610
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)28.00000.11007.190310.0000AID1473738
Voltage-dependent L-type calcium channel subunit alpha-1COryctolagus cuniculus (rabbit)IC50 (µMol)0.10700.03700.06430.1070AID755442
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)IC50 (µMol)0.22100.00131.991510.0000AID755443
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)0.00220.00032.25459.6000AID1207661
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (106)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB2007Journal of molecular biology, Dec-07, Volume: 374, Issue:4
Crystal structures of the luciferase and green fluorescent protein from Renilla reniformis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2007Journal of molecular biology, Dec-07, Volume: 374, Issue:4
Crystal structures of the luciferase and green fluorescent protein from Renilla reniformis.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1209972Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID755441Selectivity ratio of IC50 for rat voltage-dependent L-type calcium channel Cav1.3alpha-1D to IC50 for rabbit voltage-dependent L-type calcium channel Cav1.2alpha-1C2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID537140Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473793AUC in human at 2.5 to 20 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473794Drug concentration at steady state in human at 2.5 to 20 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1207661Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1209973Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1209974Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID747940Selectivity ratio of IC50 for rabbit CaV1.2alpha1C to IC50 for rat CaV1.3alpha1D2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID755438Selectivity ratio of inhibition for rat voltage-dependent L-type calcium channel Cav1.3alpha-1D to inhibition for rabbit voltage-dependent L-type calcium channel Cav1.2alpha-1C at 0.3 uM2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID537139Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1210016Inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1473795Ratio of drug concentration at steady state in human at 2.5 to 20 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1210015Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID755442Antagonist activity at rabbit voltage-dependent L-type calcium channel Cav1.2alpha-1C expressed in HEK293 cells by FLIPR assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1210017Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 8 mins by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID764454Anticonvulsant activity in Wistar albino rat assessed as protection against maximum electric shock-induced hind limb tonic extension administered 1 hr followed by maximum electric shock induction2013European journal of medicinal chemistry, Aug, Volume: 66Design, synthesis and evaluation of dialkyl 4-(benzo[d][1,3]dioxol-6-yl)-1,4-dihydro-2,6-dimethyl-1-substituted pyridine-3,5-dicarboxylates as potential anticonvulsants and their molecular properties prediction.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID755443Antagonist activity at rat voltage-dependent L-type calcium channel Cav1.3alpha-1D expressed in HEK293 cells by FLIPR assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID681353TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in F4-6RADR cells1992Biochemical pharmacology, Jun-23, Volume: 43, Issue:12
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID29363Dissociation constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID8617Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1346676Mouse Cav1.2 (Voltage-gated calcium channels)2004The Journal of clinical investigation, May, Volume: 113, Issue:10
Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels.
AID1346650Human Cav1.3 (Voltage-gated calcium channels)2001The Journal of biological chemistry, Jun-22, Volume: 276, Issue:25
alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages.
AID1346650Human Cav1.3 (Voltage-gated calcium channels)2009Molecular pharmacology, Feb, Volume: 75, Issue:2
Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,365)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990229 (16.78)18.7374
1990's873 (63.96)18.2507
2000's149 (10.92)29.6817
2010's87 (6.37)24.3611
2020's27 (1.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.88 (24.57)
Research Supply Index7.47 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index89.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials346 (24.66%)5.53%
Reviews0 (0.00%)6.00%
Reviews57 (4.06%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies6 (0.43%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
Other994 (70.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Impact of Persistent Conductances on Motor Unit Firing in SCI [NCT02136823]50 participants (Anticipated)Interventional2009-06-30Active, not recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Drug Discrimination in Methadone-Maintained Humans Study 2 [NCT00733239]Phase 115 participants (Actual)Interventional2008-08-31Completed
Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation [NCT03083353]Early Phase 1102 participants (Anticipated)Interventional2020-01-22Recruiting
Drug Discrimination in Methadone-Maintained Humans Study 1 [NCT00593463]Phase 140 participants (Anticipated)Interventional2006-09-30Completed
Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II [NCT00753636]Phase 231 participants (Actual)Interventional2008-04-30Completed
Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients [NCT01007994]Phase 2/Phase 333 participants (Actual)Interventional2009-11-30Completed
Adjunctive Isradipine for the Treatment of Bipolar Depression [NCT01784666]Phase 22 participants (Actual)Interventional2013-02-28Terminated(stopped due to Lack of Enrollment)
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease [NCT00909545]Phase 299 participants (Actual)Interventional2009-07-31Completed
Improving Buprenorphine Detoxification Outcomes With Isradipine [NCT01895270]Phase 1/Phase 228 participants (Actual)Interventional2013-10-31Completed
A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade [NCT01658150]11 participants (Actual)Interventional2012-09-30Completed
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease [NCT02168842]Phase 3336 participants (Actual)Interventional2014-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00753636 (7) [back to overview]Safety of the Standard Titration Schedule in PD Population as Measured by the Number of Patients That Are Able to Increase the Dose to 20 mg Daily
NCT00753636 (7) [back to overview]Tolerability of Isradipine Based on the Number of Participants That Complete the Study
NCT00753636 (7) [back to overview]Change in Motor UPDRS Scores: Baseline vs. Final Visit
NCT00753636 (7) [back to overview]Number of Participants That Completed the Study at Each Dose Level of Isradipine
NCT00753636 (7) [back to overview]Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent
NCT00753636 (7) [back to overview]Number of Participants That Tolerated Each Dose of Isradipine
NCT00753636 (7) [back to overview]Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine
NCT00909545 (32) [back to overview]Vital Signs: Change in Systolic Standing
NCT00909545 (32) [back to overview]Vital Signs: Change in Systolic Supine
NCT00909545 (32) [back to overview]Common Adverse Events: Back Pain
NCT00909545 (32) [back to overview]Common Adverse Events: Constipation
NCT00909545 (32) [back to overview]Common Adverse Events: Depression
NCT00909545 (32) [back to overview]Common Adverse Events: Diarrhoea
NCT00909545 (32) [back to overview]Common Adverse Events: Dizziness
NCT00909545 (32) [back to overview]Common Adverse Events: Dyspepsia
NCT00909545 (32) [back to overview]Common Adverse Events: Fatigue
NCT00909545 (32) [back to overview]Common Adverse Events: Headache
NCT00909545 (32) [back to overview]Common Adverse Events: Hypotension
NCT00909545 (32) [back to overview]Common Adverse Events: Insomnia
NCT00909545 (32) [back to overview]Common Adverse Events: Nasopharyngitis
NCT00909545 (32) [back to overview]Common Adverse Events: Nausea
NCT00909545 (32) [back to overview]Common Adverse Events: Oedema Peripheral
NCT00909545 (32) [back to overview]Common Adverse Events: Sinusitis
NCT00909545 (32) [back to overview]Common Adverse Events: Somnolence
NCT00909545 (32) [back to overview]Common Adverse Events: Upper Respiratory Tract Infection
NCT00909545 (32) [back to overview]Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale
NCT00909545 (32) [back to overview]Efficacy: Change in Beck Depression Inventory II (BDI-II)
NCT00909545 (32) [back to overview]Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale
NCT00909545 (32) [back to overview]Efficacy: Change in Modified Hoehn & Yahr Scale
NCT00909545 (32) [back to overview]Efficacy: Change in Modified Schwab & England Independence Scale
NCT00909545 (32) [back to overview]Efficacy: Change in Montreal Cognitive Assessment
NCT00909545 (32) [back to overview]Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale
NCT00909545 (32) [back to overview]Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)
NCT00909545 (32) [back to overview]Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)
NCT00909545 (32) [back to overview]Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.
NCT00909545 (32) [back to overview]Vital Signs: Change in Diastolic Standing
NCT00909545 (32) [back to overview]Vital Signs: Change in Diastolic Supine
NCT00909545 (32) [back to overview]Vital Signs: Change in Pulse Standing
NCT00909545 (32) [back to overview]Vital Signs: Change in Pulse Supine
NCT01007994 (1) [back to overview]Number of Participants Who Are Non Dippers
NCT01658150 (16) [back to overview]Quality of Life (QoL) Scale
NCT01658150 (16) [back to overview]UPSA Communication Score
NCT01658150 (16) [back to overview]Abnormal Involuntary Movement Scale (AIMS)
NCT01658150 (16) [back to overview]Brief Psychiatric Rating Scale (BPRS)
NCT01658150 (16) [back to overview]Clinical Global Impression Scale (CGI)
NCT01658150 (16) [back to overview]Clinician Administered Rating Scale for Mania (CARS-M)
NCT01658150 (16) [back to overview]Hamilton Rating Scale for Depression (HRSD)
NCT01658150 (16) [back to overview]Mean Change in PRISE Adverse Event Checklist Score
NCT01658150 (16) [back to overview]Modified Simpson Angus Scale (MSAS)
NCT01658150 (16) [back to overview]Number of Participants With a Confirmed SCID-IV
NCT01658150 (16) [back to overview]Number of Participants With Suicidal Acknowledgments
NCT01658150 (16) [back to overview]Scale for the Assessment of Negative Symptoms (SANS)
NCT01658150 (16) [back to overview]MATRICS Consensus Cognitive Battery (MCCB) Change in Neurocognitive/Functional Measures
NCT01658150 (16) [back to overview]Number of Participants With Normal Chemistry Panel
NCT01658150 (16) [back to overview]Number of Participants With Normal Complete Blood Count (CBC)
NCT01658150 (16) [back to overview]Number of Participants With Normal ECG
NCT01784666 (1) [back to overview]Change in MADRS (4 Weeks)
NCT01895270 (1) [back to overview]Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6)
NCT02168842 (26) [back to overview]Adjusted Mean Change in Adjusted UPDRS Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in Ambulatory Capacity
NCT02168842 (26) [back to overview]Adjusted Mean Change in BDI Total Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in Diastolic BP, Seated
NCT02168842 (26) [back to overview]Adjusted Mean Change in H/Y Stage
NCT02168842 (26) [back to overview]Adjusted Mean Change in LED
NCT02168842 (26) [back to overview]Adjusted Mean Change in LED Cumulative
NCT02168842 (26) [back to overview]Adjusted Mean Change in Levodopa
NCT02168842 (26) [back to overview]Adjusted Mean Change in Levodopa Cumulative
NCT02168842 (26) [back to overview]Adjusted Mean Change in MDS-UPDRS mEDL
NCT02168842 (26) [back to overview]Adjusted Mean Change in MDS-UPDRS nmEDL
NCT02168842 (26) [back to overview]Adjusted Mean Change in MoCA Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in Modified Rankin Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in PDQ39 Total Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in SE/ADL
NCT02168842 (26) [back to overview]Adjusted Mean Change in Systolic BP, Seated
NCT02168842 (26) [back to overview]Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in UPDRS Part II
NCT02168842 (26) [back to overview]Adjusted Mean Change in UPDRS Part III OFF
NCT02168842 (26) [back to overview]Adjusted Mean Change in UPDRS Part IV
NCT02168842 (26) [back to overview]Adjusted Mean Change in UPDRS PIGD Score
NCT02168842 (26) [back to overview]Adjusted Mean Change in UPDRS Score to 1 Year
NCT02168842 (26) [back to overview]Adjusted Mean Change in UPDRS Tremor Score
NCT02168842 (26) [back to overview]Risk of Need for Antiparkinsonian Therapy
NCT02168842 (26) [back to overview]Risk of Need for Dyskinesia
NCT02168842 (26) [back to overview]Risk of Need for Fluctuations

Safety of the Standard Titration Schedule in PD Population as Measured by the Number of Patients That Are Able to Increase the Dose to 20 mg Daily

(NCT00753636)
Timeframe: 1 year

InterventionParticipants (Number)
Isradipine 20mg, 15mg, 10mg or 5 mg16

[back to top]

Tolerability of Isradipine Based on the Number of Participants That Complete the Study

(NCT00753636)
Timeframe: 1 year

InterventionParticipants (Number)
Isradipine 20mg, 15mg, 10mg or 5 mg25

[back to top]

Change in Motor UPDRS Scores: Baseline vs. Final Visit

"Baseline visit = Week 0 Final visit = Week 12~Unified Parkinson's Disease Rating Scale (UPDRS)is made up of the following sections:~Part I: evaluation of Mentation, behavior, and mood Part II: self evaluation of the activities of daily life Part III: clinician-scored motor evaluation Part IV: Hoehn and Yahr stating of severity of Parkinson disease. Part V: Schwab and England ADL scale Only part three was used for this assessment.~The higher the UPDRS score, the greater the disability from PD.~The range for scores for Section III is 0 to 108." (NCT00753636)
Timeframe: 12 weeks

InterventionUPDRS Part III Score (Mean)
BaselineFinal
Isradipine 20mg, 15mg, 10mg or 5 mg7.617.08

[back to top]

Number of Participants That Completed the Study at Each Dose Level of Isradipine

(NCT00753636)
Timeframe: 1 year

InterventionParticipants (Number)
20mg15mg10mg5mg
Isradipine 20mg, 15mg, 10mg or 5 mg16441

[back to top]

Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent

"At the time of enrollment, some patients were currently being treated with antihypertensive agents including Propanolol, Toprol, Lisinopril, Diovan, Norvasc.~HTN+: Participants on an antihypertensive agent HTN-: Participants not on an antihypertensive agent" (NCT00753636)
Timeframe: 1 year

InterventionParticipants (Number)
HTN+ 20mgHTN+ 15mgHTN+ 10 mgHTN+ 5mgHTN- 20mgHTN- 15mgHTN- 10mgHTN- 5mg
Isradipine 20mg, 15mg, 10mg or 5 mg231014254

[back to top]

Number of Participants That Tolerated Each Dose of Isradipine

Tolerability= maximum tolerated dose (NCT00753636)
Timeframe: 1 year

InterventionParticipants (Number)
20mg15mg10mg5mg
Isradipine 20mg, 15mg, 10mg or 5 mg16564

[back to top]

Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine

Mean Plasma Concentration (+/- SD ng/mL) (NCT00753636)
Timeframe: 1 year

Interventionng/mL (Mean)
20 mg15 mg10 mg5 mg
Isradipine 20mg, 15mg, 10mg or 5 mg2.482.531.530.68

[back to top]

Vital Signs: Change in Systolic Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo-4.77
Isradipine CR 5mg/Day-9.85
Isradipine CR 10mg/Day-7.75
Isradipine CR 20mg/Day-6.30

[back to top]

Vital Signs: Change in Systolic Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo-2.45
Isradipine CR 5mg/Day-8.59
Isradipine CR 10mg/Day-6.45
Isradipine CR 20mg/Day-7.01

[back to top]

Common Adverse Events: Back Pain

Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day0
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day3

[back to top]

Common Adverse Events: Constipation

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day3
Isradipine CR 20mg/Day4

[back to top]

Common Adverse Events: Depression

Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day1

[back to top]

Common Adverse Events: Diarrhoea

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day1

[back to top]

Common Adverse Events: Dizziness

Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo7
Isradipine CR 5mg/Day5
Isradipine CR 10mg/Day6
Isradipine CR 20mg/Day6

[back to top]

Common Adverse Events: Dyspepsia

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day1

[back to top]

Common Adverse Events: Fatigue

General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day3
Isradipine CR 20mg/Day3

[back to top]

Common Adverse Events: Headache

Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day6
Isradipine CR 20mg/Day4

[back to top]

Common Adverse Events: Hypotension

Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day2

[back to top]

Common Adverse Events: Insomnia

Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day1

[back to top]

Common Adverse Events: Nasopharyngitis

Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day4
Isradipine CR 10mg/Day7
Isradipine CR 20mg/Day4

[back to top]

Common Adverse Events: Nausea

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day2

[back to top]

Common Adverse Events: Oedema Peripheral

General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day4
Isradipine CR 10mg/Day10
Isradipine CR 20mg/Day16

[back to top]

Common Adverse Events: Sinusitis

Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day0

[back to top]

Common Adverse Events: Somnolence

Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day0

[back to top]

Common Adverse Events: Upper Respiratory Tract Infection

Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day5
Isradipine CR 20mg/Day0

[back to top]

Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo2.60
Isradipine CR 5mg/Day3.20
Isradipine CR 10mg/Day2.09
Isradipine CR 20mg/Day1.86

[back to top]

Efficacy: Change in Beck Depression Inventory II (BDI-II)

The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo-0.52
Isradipine CR 5mg/Day1.99
Isradipine CR 10mg/Day0.11
Isradipine CR 20mg/Day1.50

[back to top]

Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo0.30
Isradipine CR 5mg/Day0.76
Isradipine CR 10mg/Day0.30
Isradipine CR 20mg/Day0.03

[back to top]

Efficacy: Change in Modified Hoehn & Yahr Scale

The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo0.27
Isradipine CR 5mg/Day0.22
Isradipine CR 10mg/Day0.12
Isradipine CR 20mg/Day0.11

[back to top]

Efficacy: Change in Modified Schwab & England Independence Scale

The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo-5.04
Isradipine CR 5mg/Day-5.56
Isradipine CR 10mg/Day-3.69
Isradipine CR 20mg/Day-3.76

[back to top]

Efficacy: Change in Montreal Cognitive Assessment

The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo0.58
Isradipine CR 5mg/Day0.06
Isradipine CR 10mg/Day0.11
Isradipine CR 20mg/Day0.36

[back to top]

Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo4.32
Isradipine CR 5mg/Day3.49
Isradipine CR 10mg/Day3.91
Isradipine CR 20mg/Day3.69

[back to top]

Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)

The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo1.28
Isradipine CR 5mg/Day3.47
Isradipine CR 10mg/Day3.00
Isradipine CR 20mg/Day3.35

[back to top]

Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

InterventionScores on a scale (Least Squares Mean)
Placebo7.40
Isradipine CR 5mg/Day7.44
Isradipine CR 10mg/Day6.30
Isradipine CR 15-20mg/Day5.40

[back to top]

Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.

Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo25
Isradipine CR 5mg/Day19
Isradipine CR 10mg/Day19
Isradipine CR 20mg/Day9

[back to top]

Vital Signs: Change in Diastolic Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo-0.38
Isradipine CR 5mg/Day-4.20
Isradipine CR 10mg/Day-5.14
Isradipine CR 20mg/Day-4.34

[back to top]

Vital Signs: Change in Diastolic Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo0.09
Isradipine CR 5mg/Day-2.79
Isradipine CR 10mg/Day-4.54
Isradipine CR 20mg/Day-3.63

[back to top]

Vital Signs: Change in Pulse Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionbeats per minute (Least Squares Mean)
Placebo-0.08
Isradipine CR 5mg/Day-2.98
Isradipine CR 10mg/Day-2.29
Isradipine CR 20mg/Day-1.21

[back to top]

Vital Signs: Change in Pulse Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionbeats per minute (Least Squares Mean)
Placebo-0.42
Isradipine CR 5mg/Day-0.71
Isradipine CR 10mg/Day-0.52
Isradipine CR 20mg/Day0.18

[back to top]

Number of Participants Who Are Non Dippers

Percentage of subjects in each of the treatment arms who are nondippers, defined as systolic or diastolic nocturnal dip <10% (NCT01007994)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
New Medication7
Control12

[back to top]

Quality of Life (QoL) Scale

The QoL is a measure of the perceived satisfaction in an individual's daily life. This 16-item self-report measure is rated on a 7-point scale, ranging from 1 (terrible) to 7 (delighted), with a total score range from 16-112, where higher scores indicate higher satisfaction with daily life. (NCT01658150)
Timeframe: baseline and Week 4

Interventionscore on a scale (Mean)
BaselineWeek 4
Isradipine96.593.0

[back to top]

UPSA Communication Score

UCSD Performance Skills Assessment (UPSA) - The UPSA is performance-based measure of real-world daily functioning abilities. Participants receive scores for the communication subscale (range = 0-20), with higher score indicating better neurocognitive functioning (NCT01658150)
Timeframe: baseline and week 4

Interventionscore on a scale (Mean)
baselineweek 4
Isradipine15.316.5

[back to top]

Abnormal Involuntary Movement Scale (AIMS)

Mean change for abnormal involuntary movements throughout the study. The AIMS is a physician-administered scale of abnormal involuntary movements. AIMS consists of 10 items, each defined by a series of movements. Each item is rated on a 5-point scale, ranging from 0 (not observed) to 4 (severe), with a total score range from 0-40, where higher scores indicate abnormal involuntary movements. (NCT01658150)
Timeframe: baseline and Week 4

Interventionscore on a scale (Mean)
Isradipine0.7

[back to top]

Brief Psychiatric Rating Scale (BPRS)

Mean change for positive symptoms throughout the study. BPRS consists of 18 items, each defined by a series of symptoms. Each item is rated on a 7-point scale, ranging from 1 (not observed) to 7 (very severe), with a total score range from 18-126, where higher scores indicate psychiatric symptoms. (NCT01658150)
Timeframe: up to 4 weeks

Interventionscore on a scale (Mean)
Isradipine-1.0

[back to top]

Clinical Global Impression Scale (CGI)

Mean change of clinical impression of severity of psychiatric illness throughout the study. CGI consists of one item, defined by severity of illness. It is rated on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients), with a total range score of 1-7, where higher score indicates severity of illness. (NCT01658150)
Timeframe: up to 4 weeks

Interventionscore on a scale (Mean)
Isradipine-0.2

[back to top]

Clinician Administered Rating Scale for Mania (CARS-M)

Mean change of symptoms of mania throughout the study. CARS-M contains 14 items rated from 0 (absent) to 5 (present) and one item scored 0 to 4, with total range from 0 to 74, where higher score indicates manic symptoms. (NCT01658150)
Timeframe: up to 4 weeks

Interventionscore on a scale (Mean)
Isradipine0

[back to top]

Hamilton Rating Scale for Depression (HRSD)

Mean change of symptoms of depression throughout the study. HRSD consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe), with a total score range of 0-56, where higher score indicates more depressive symptoms (NCT01658150)
Timeframe: up to 4 weeks

Interventionscore on a scale (Mean)
Isradipine-0.6

[back to top]

Mean Change in PRISE Adverse Event Checklist Score

The PRISE is a physician-administered checklist of adverse events. PRISE contains 33 items, each defined by an adverse event. Each item is rated on a 3-point scale, ranging from 0 (not present) to 2 (distressing), with a total score range from 0-66, where higher scores indicate more adverse events. Mean change for adverse events at week 4 as compared to baseline (NCT01658150)
Timeframe: up to 4 weeks

Interventionscore on a scale (Mean)
Isradipine-0.7

[back to top]

Modified Simpson Angus Scale (MSAS)

Mean change for drug-induced disordered movement throughout the study. The MSAS is a physician-administered scale of abnormal drug-induced movements. MSAS consists of 6 items, each defined by a series of movements. Each item is rated on a 5-point scale, ranging form 0 (not observed) to 4 (most severe), with a total range of 0-24, where higher scores indicate drug-induced disordered movement. (NCT01658150)
Timeframe: baseline and week 4

Interventionscore on a scale (Mean)
Isradipine-0.3

[back to top]

Number of Participants With a Confirmed SCID-IV

Number of participants with confirm diagnosis for inclusion into study using the Structured Clinical Interview for the DSM-IV (SCID-IV) (NCT01658150)
Timeframe: baseline

InterventionParticipants (Count of Participants)
Isradipine10

[back to top]

Number of Participants With Suicidal Acknowledgments

Number of participants with Suicidal acknowledgements based on the Columbia Suicide Severity Rating Scales (C-SSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation). (NCT01658150)
Timeframe: up to 4 weeks

InterventionParticipants (Count of Participants)
Isradipine0

[back to top]

Scale for the Assessment of Negative Symptoms (SANS)

Mean change of negative symptoms throughout the study. SANS consists of 22 items, each defined by a series of symptoms. Each item is rated on a 6-point scale, ranging from 0 (no presence) to 5 (severe presence), with a total range of 0-110, where higher scores indicate negative symptoms. (NCT01658150)
Timeframe: up to 4 weeks

Interventionscore on a scale (Mean)
Isradipine-1.6

[back to top]

MATRICS Consensus Cognitive Battery (MCCB) Change in Neurocognitive/Functional Measures

MATRICS Consensus Cognitive Battery (MCCB) as measure of Neurocognitive/Functional Measures is a standardized battery designed to measure cognitive functioning in people with schizophrenia. The MCCB is represented as a composite T score. A t score is a type of standard score computed by multiplying a z-score (how many standard deviations an element is from the mean) by 10 and adding 50. (NCT01658150)
Timeframe: baseline and week 4

Interventionz-score (Mean)
BaselineWeek 4
Isradipine39.838.2

[back to top]

Number of Participants With Normal Chemistry Panel

Number of participants with normal chemistry panel to confirm inclusion into study at baseline and week (NCT01658150)
Timeframe: baseline and week 4

InterventionParticipants (Count of Participants)
BaselineWeek 4
Isradipine1010

[back to top]

Number of Participants With Normal Complete Blood Count (CBC)

Number of participants with normal CBC to confirm inclusion into study at baseline and week 4 (NCT01658150)
Timeframe: baseline and week 4

InterventionParticipants (Count of Participants)
BaselineWeek 4
Isradipine1010

[back to top]

Number of Participants With Normal ECG

Number of participants with normal ECG readings to confirm inclusion into study and compared at week 4 to baseline (NCT01658150)
Timeframe: baseline and week 4

InterventionParticipants (Count of Participants)
BaselineWeek 4
Isradipine1010

[back to top]

Change in MADRS (4 Weeks)

"Change in Montgomery-Asberg Depression Rating Scale (MADRS) in isradipine-treated epochs versus placebo-treated epochs.~These scores represent total scores, and on the MADRS total scores range from 0-60. A higher score indicates increased depression severity." (NCT01784666)
Timeframe: Baseline vs week 4 (and, for placebo nonresponders in 1st 4 weeks, week 8 vs week 4)

Interventionscores on a scale (Number)
Isradipine-Isradipine-9
Placebo-Placebo0

[back to top]

Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6)

Illicit results via urine toxicology screens for heroin and several opioids will be measured thrice weekly during the taper (NCT01895270)
Timeframe: thrice weekly for approx 2 weeks (taper)

Interventionopioid-positive urine (Least Squares Mean)
Isradipine-1.25
Placebo-0.36

[back to top]

Adjusted Mean Change in Adjusted UPDRS Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the adjusted UPDRS Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of adjusted UPDRS ranges from -100 to 150, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine13.49
Placebo (for Isradipine)13.85

[back to top]

Adjusted Mean Change in Ambulatory Capacity

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Ambulatory Capacity in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Ambulatory Capacity ranges from -4 to 12, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine0.59
Placebo (for Isradipine)0.50

[back to top]

Adjusted Mean Change in BDI Total Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the BDI Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in BDI Total Score ranges from -9 to 22, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine0.77
Placebo (for Isradipine)1.34

[back to top]

Adjusted Mean Change in Diastolic BP, Seated

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Diastolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Diastolic BP, Seated ranges from -35 to 25. larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

InterventionmmHg (Least Squares Mean)
Isradipine-4.64
Placebo (for Isradipine)-0.71

[back to top]

Adjusted Mean Change in H/Y Stage

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the H/Y Stage in the active treatment arm versus placebo between the baseline and 36 month visit. The change in H/Y Stage ranges from -1 to 3, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine0.15
Placebo (for Isradipine)0.21

[back to top]

Adjusted Mean Change in LED

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -100 to 3000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionmg (Least Squares Mean)
Isradipine389
Placebo (for Isradipine)375

[back to top]

Adjusted Mean Change in LED Cumulative

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED cumulative ranges from 0 to 1200000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionmg (Least Squares Mean)
Isradipine676
Placebo (for Isradipine)697

[back to top]

Adjusted Mean Change in Levodopa

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -200 to 2000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionmg (Least Squares Mean)
Isradipine307
Placebo (for Isradipine)307

[back to top]

Adjusted Mean Change in Levodopa Cumulative

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa Cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of Levodopa cumulative ranges from 0 to 800000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionmg (Least Squares Mean)
Isradipine471
Placebo (for Isradipine)508

[back to top]

Adjusted Mean Change in MDS-UPDRS mEDL

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS mEDL(Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS mEDL ranges from -8 to 35, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine2.32
Placebo (for Isradipine)2.57

[back to top]

Adjusted Mean Change in MDS-UPDRS nmEDL

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS nmEDL ranges from -6 to 10, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine1.93
Placebo (for Isradipine)1.76

[back to top]

Adjusted Mean Change in MoCA Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MoCA Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MoCA Score ranges from -10 to 6, larger value shows improvement of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine-0.04
Placebo (for Isradipine)-0.07

[back to top]

Adjusted Mean Change in Modified Rankin Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Modified Rankin Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Modified Rankin Score ranges from -1 to 3, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine0.18
Placebo (for Isradipine)0.29

[back to top]

Adjusted Mean Change in PDQ39 Total Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the PDQ39 Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in PDQ39 Total Score ranges from -16 to 44, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine2.80
Placebo (for Isradipine)3.42

[back to top]

Adjusted Mean Change in SE/ADL

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the SE/ADL in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -70 to 20, larger value shows improvement of PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine-4.14
Placebo (for Isradipine)-4.41

[back to top]

Adjusted Mean Change in Systolic BP, Seated

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Systolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Systolic BP, Seated ranges from -65 to 50. larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

InterventionmmHg (Least Squares Mean)
Isradipine-6.11
Placebo (for Isradipine)1.03

[back to top]

Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the total (Part I-III) UPDRS score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -30 to 80, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine2.99
Placebo (for Isradipine)3.26

[back to top]

Adjusted Mean Change in UPDRS Part II

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part II (ADL Function) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part II ranges from -12 to 19, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine2.3
Placebo (for Isradipine)2.5

[back to top]

Adjusted Mean Change in UPDRS Part III OFF

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part III OFF rating in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part III OFF ranges from -30 to 100, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine4.60
Placebo (for Isradipine)4.50

[back to top]

Adjusted Mean Change in UPDRS Part IV

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part IV in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part IV ranges from -10 to 10, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine1.18
Placebo (for Isradipine)1.07

[back to top]

Adjusted Mean Change in UPDRS PIGD Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS PIGD Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS PIGD Score ranges from -1 to 3, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine0.12
Placebo (for Isradipine)0.10

[back to top]

Adjusted Mean Change in UPDRS Score to 1 Year

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 12 month visit. The change of UPDRS ranges from -22 to 23, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 12 months of treatment

Interventionscore on a scale (Least Squares Mean)
Isradipine4.65
Placebo (for Isradipine)5.3

[back to top]

Adjusted Mean Change in UPDRS Tremor Score

Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Tremor Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Tremor Score ranges from -1 to 2, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionunits on a scale (Least Squares Mean)
Isradipine0.00
Placebo (for Isradipine)0.01

[back to top]

Risk of Need for Antiparkinsonian Therapy

Number of participants with need for Antiparkinsonian Therapy. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionparticipants (Number)
Isradipine145
Placebo (for Isradipine)147

[back to top]

Risk of Need for Dyskinesia

Number of participants with need for Dyskinesia Therapy. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionparticipants (Number)
Isradipine24
Placebo (for Isradipine)19

[back to top]

Risk of Need for Fluctuations

Number of participants with need for Fluctuations Therapy. (NCT02168842)
Timeframe: Baseline to 36 months of treatment

Interventionparticipants (Number)
Isradipine57
Placebo (for Isradipine)64

[back to top]